NCT02998320

Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

Evaluation of Compliance With Treatment by Elvitegravir/Cobicistat/FTC/Tenofovir Alafenamide (E/C/F/TAF) in HIV Post-exposure Prophylaxis (to Infected Blood or Sexual Contact)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 101 (actual)
• Sponsor: Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks

Detailed description

This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Elvitegravir/Cobicistat/FTC/Tenofovir alafenamide (E/C/F/TAF) for four Weeks. Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Cobicistat is a selective, mechanism-based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A subfamily. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue àf 2'-dexicytidine. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue).

Conditions

• HIV Risk

Interventions

Type	Name	Description
DRUG	Genvoya	Oral use (one tablet each day); 150/150/200/10 mg; 28 days

Timeline

• Start date: 2017-03-10
• Primary completion: 2018-06-30
• Completion: 2018-09-30
• First posted: 2016-12-20
• Last updated: 2019-02-15

Locations

16 sites across 1 country: France